CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Light4Sight is developing a novel drug delivery system for treating chronic eye diseases. It uses self-assembling nanocarriers within a light-sensitive hydrogel to release therapeutic peptides on demand, reducing the need for frequent injections and improving patient comfort.
In 2016, the global sales of biopharmaceutical drugs (protein, peptides) in ophthalmic applications exceeded $8 billion and is estimated to increase to $35.7 billion by 2025.
The growth of the ophthalmic drug market is primarily driven by an increasing aged population suffering from age- and lifestyle-related diseases such as macular degeneration, diabetic retinopathy, glaucoma, among others.
These diseases cause moderate or complete vision loss, resulting in significant reduction in quality of…
QUEEN MARY UNIVERSITY OF LONDON
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
